Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Thomas Müller. (2017) Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease. Expert Opinion on Pharmacotherapy 18:14, pages 1457-1465.
Read now
Read now
F. Javier Álvarez. (2016) Parkinson’s disease, antiparkinson medicines, and driving. Expert Review of Neurotherapeutics 16:9, pages 1023-1032.
Read now
Read now
Félix Javier Jiménez-Jiménez, Hortensia Alonso-Navarro, Elena García-Martín & José A. G. Agúndez. (2016) Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 433-448.
Read now
Read now
Cornelis J Van der Schyf. (2015) Rational drug discovery design approaches for treating Parkinson’s disease. Expert Opinion on Drug Discovery 10:7, pages 713-741.
Read now
Read now
Thomas Müller. (2014) Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 10:10, pages 1423-1432.
Read now
Read now
Articles from other publishers (15)
Suresh Thirunavukarasu, Balasubramanian Bala Venkata Ramanan, Sathya Krishnan Suresh, Vincent Jayakumar Antonisamy, Devi Varadharaj, Paranjothi Shanmugam, Kavita Verma, Canmany Elumalai, Gladson Selvakumar, Ahila Elumalai, Lydia Prabahar, Hridwik Adiyeri Janardhanan & Anoop UR. (2023) The Administration of Levodopa in a Patient With Parkinson’s Disease Using a Novel Maxillofacial Route: A First-in-Human Report. Cureus.
Crossref
Crossref
Lei Wang, Xinghong Wu, Ge Yang, Nan Hu, Zijian Zhao, Lei Zhao & Shengyu Li. (2022) Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson’s Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation. Neuroscience 498, pages 64-72.
Crossref
Crossref
Mohammad Al Majali, Michael Sunnaa & Pratap Chand. (2021) Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease. Journal of Geriatric Psychiatry and Neurology 34:4, pages 263-273.
Crossref
Crossref
Abhijeet Kulkarni, Mahesh Shinde, Gaurav Sonawane, Hitesh Raotole, Rohit Pande & Chandrakantsing V. Pardeshi. 2021. Direct Nose-to-Brain Drug Delivery. Direct Nose-to-Brain Drug Delivery
329
349
.
Meng Huang, Xiao Gu & Xiaoling Gao. 2019. Brain Targeted Drug Delivery System. Brain Targeted Drug Delivery System
321
356
.
Delphine Charvin, Rossella Medori, Robert A. Hauser & Olivier Rascol. (2018) Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nature Reviews Drug Discovery 17:11, pages 804-822.
Crossref
Crossref
Peter Riederer & Thomas Müller. (2018) Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects. Journal of Neural Transmission 125:11, pages 1751-1757.
Crossref
Crossref
Jason Margolesky & Carlos Singer. (2017) Extended-release oral capsule of carbidopa–levodopa in Parkinson disease. Therapeutic Advances in Neurological Disorders 11, pages 175628561773772.
Crossref
Crossref
Yıldız Değirmenci. (2017) Treatment strategies in advanced Parkinson's disease: Review of the literature. Cumhuriyet Medical Journal 39:3, pages 509-517.
Crossref
Crossref
Liang Xiao-feng, Zhu Wen-ting, Xu Yuan-yuan, Lai Chong-Fa, Zheng Lu, Rao Jin-jun & Wang Wen-ya. (2016) Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease. European Journal of Pharmacology 791, pages 348-354.
Crossref
Crossref
Thomas Müller. (2016) Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. Neurodegenerative Disease Management 6:5, pages 385-398.
Crossref
Crossref
John C. Morgan & Susan H. Fox. (2016) Treating the Motor Symptoms of Parkinson Disease. CONTINUUM: Lifelong Learning in Neurology 22:4, pages 1064-1085.
Crossref
Crossref
Daphne Atlas. (2016)
DopAmide: Novel, Water-Soluble, Slow-Release
l
-dihydroxyphenylalanine (
l
-DOPA) Precursor Moderates
l
-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons
. CNS Neuroscience & Therapeutics 22:6, pages 461-467.
Crossref
Crossref
Sarah L. Greig & Kate McKeage. (2015) Carbidopa/Levodopa ER Capsules (Rytary®, Numient™): A Review in Parkinson’s Disease. CNS Drugs 30:1, pages 79-90.
Crossref
Crossref
Juan C. Giugni & Michael S. Okun. (2014) Treatment of advanced Parkinson's disease. Current Opinion in Neurology 27:4, pages 450-460.
Crossref
Crossref